Skip to main content
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. — Investor Relations & Filings

Ticker · MCRB ISIN · US81750R2013 LEI · 549300GMXBE5NUWISF13 US Manufacturing
Open in API
Filings indexed 668 across all filing types
Latest filing 2022-06-30 Capital/Financing Update
Country US United States of America
Listing US MCRB

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Seres Therapeutics, Inc. is a commercial-stage biotechnology company developing microbiome-based therapeutics. The company's platform creates a novel class of biological drugs, known as live biotherapeutics, which consist of rationally selected consortia of live bacteria. These therapies are designed to modulate the functional properties of the gastrointestinal microbiome to treat and prevent diseases. Seres' development programs target medically vulnerable patient populations, with a focus on preventing bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as treating gastrointestinal-related immune diseases.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 29, 2022, by Seres Therapeutics, Inc. It reports the entry into material definitive agreements related to a securities purchase agreement and a placement agency agreement for a registered direct offering. The content focuses on financing activities, including the issuance and sale of common stock and the expected proceeds and use of funds. There are no financial statements or detailed financial performance data included, only descriptions of financing transactions and agreements. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 10,000 characters, indicating it is not a brief announcement but a substantive filing. Therefore, the appropriate classification is CAP with high confidence.
2022-06-30 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a registered direct offering of common stock. It details the offering size, pricing, placement agent fees, and other terms of the stock offering. The document includes risk factors, use of proceeds, dividend policy, dilution, plan of distribution, and legal matters sections typical of a capital raising filing. It is not a financial report, earnings release, or management discussion, but rather a detailed disclosure related to a capital raising transaction. Therefore, it fits the definition of a Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or regulatory filing. Confidence is high due to clear identification of offering details and regulatory references to Rule 424(b)(5).
2022-06-30 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-24 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-24 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-24 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-24 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.